Article

Inhibition of methicillin-resistant Staphylococcus aureus by an in vitro continuous-flow culture containing human stool microflora

Research Section, Louis Stokes Cleveland Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA.
FEMS Microbiology Letters (Impact Factor: 2.72). 01/2005; 241(2):201-5. DOI: 10.1016/j.femsle.2004.10.021
Source: PubMed

ABSTRACT We used an in vitro continuous-flow culture model of human stool microflora to examine the ability of human stool microflora to inhibit growth of two methicillin-resistant S. aureus (MRSA) strains. Continuous-flow cultures consistently eliminated MRSA inocula of 10(6) cfu/mL within 4 days, and addition of continuous-flow culture resulted in elimination of a pre-established MRSA culture ( approximately 10(8) cfu/mL) within 6-8 days. Anaerobic or "aerobic" (i.e., continuous bubbling of room air to eliminate obligate anaerobes) cultures eliminated MRSA at similar rates. The MRSA strains were unable to replicate under anaerobic conditions in sterile filtrates produced from the continuous-flow culture, but rapid growth occurred when glucose was added. These data demonstrate that indigenous stool microflora efficiently eliminate MRSA colonization and obligate anaerobes are not essential for inhibition. Our findings also suggest that inhibition of MRSA in continuous-flow cultures is due to depletion of nutrients rather than production of inhibitory conditions.

Download full-text

Full-text

Available from: Nicole J Davis, Jan 07, 2015
0 Followers
 · 
61 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In dieser Arbeit wurde das in vitro Wachstumsverhalten ausgesuchter MRSA in Konkurrenz zu Bakterien der Standortflora unter Optimalbedingungen und unter Mangelbedingungen getestet. Es lässt sich für alle getesteten MRSA-Stämme zusammenfassend sagen, dass ihre klinische Prävalenz nicht mit dem Wachstum in vitro korreliert, d.h. das häufige Spa-Typen nicht besser unter unseren Versuchbedingungen gewachsen sind als seltene. In vitro konnte kein verdrängendes Wachstum des Methicillin sensiblen S. aureus gegenüber den resistenten Stämme beobachtet werden. Vielmehr gelingt es den MRSA-Stämmen, ein Wachstumsgemisch zu ihrem Vorteil zu beeinflussen, indem sie die getesteten anderen Mikroorganismen (S. epidermidis, S. cerivisiae) im Wachstum hemmen, mit Ausnahme von E. faecium. Die Arbeit beleuchtet die Schwierigkeiten der Identifizierung von probiotischen Arten zur Verdrängung eines MRSA. In Zukunft sollte vielleicht an der Optimierung von in vitro Systemen gearbeitet werden (in vitro Organkulturen) oder Tiermodelle verwendet werden. Den Transmissionsunterschieden und der Tenazität sind weiterhin Aufmerksamkeit zu widmen. Wie in der Literatur beschrieben ist es zum Verständnis des Wachstumsverhal-tens der resistenten Stämme wichtig zu wissen, auf welchen molekularbiologischen Grundlagen die Resistenz beruht, da eine einzelne Site-Mutation zusätzliche Resistenzen bedeuten und einen eventuellen Wachstumsnachteil wieder ausgleichen kann. Im Klinikalltag scheinen sich die MRSA-Stämme auszubreiten, die den Wachstumsnachteil bereits ausgeglichen haben, beziehungsweise deren Methicillinresistenz keinen Wachstumsnachteil bedeutet. The competitive in vitro growth of selected MRSA-Clones in comparison to bacteria from the human skin and probiotic bacteria respectively are evaluated in this study. There was no proof of in vitro growth advantage for the common MRSA-Clones in comparison to the uncommonly found MRSA-Clones in clinical samples. This concludes that there must be a different reason for the spreading of the commonly found MRSA-Clones other than the growth rate. The competitive growth analysis with bacteria of the human skin (S. epidermidis, Methicillin susceptible S. aureus), E. faecium and probiotic bacteria (S. cerivisiae) showed, that none of the tested bacteria could decrease the growth rate of the MRSA-Clones in clinical relevant concentrations. Methicillin resistence shows a growth rate decrease for some MRSA-clones as described in the literature. By contrast, the results of this study reveal, that the clinical acquired MRSA-clones must have somehow compensated for the growth disadvantage.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intestinal colonization by methicillin-resistant Staphylococcus aureus (MRSA) is common in some groups of hospitalized patients and has been associated with an increased risk of staphylococcal infection. We tested the hypothesis that growth of MRSA in the colonic mucus layer is required for establishment of intestinal colonization. Mice treated with oral streptomycin before oral administration of MRSA developed persistent intestinal colonization, and the cecal mucus layer contained high concentrations of MRSA. MRSA strains grew rapidly when inoculated into cecal mucus in vitro but were unable to replicate under anaerobic conditions in cecal contents of saline- or streptomycin-treated mice. Oral vancomycin treatment reduced the density of 1 MRSA strain in stool but had no effect on a second strain. These results suggest that the cecal mucus layer provides an important niche that facilitates intestinal colonization by MRSA. Oral nonabsorbed antibiotics may be ineffective in eradicating some MRSA strains from the intestinal tract.
    The Journal of Infectious Diseases 12/2005; 192(9):1621-7. DOI:10.1086/491737 · 5.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently available antimicrobials exhibit broad killing with regard to bacterial genera and species. Indiscriminate killing of microbes by these conventional antibiotics can disrupt the ecological balance of the indigenous microbial flora, often resulting in negative clinical consequences. Species-specific antimicrobials capable of precisely targeting pathogenic bacteria without damaging benign microorganisms provide a means of avoiding this problem. In this communication, we report the successful creation of the first synthetic, target-specific antimicrobial peptide, G10KHc, via addition of a rationally designed Pseudomonas-specific targeting moiety (KH) to a generally killing peptide (novispirin G10). The resulting chimeric peptide showed enhanced bactericidal activity and faster killing kinetics against Pseudomonas spp. than G10 alone. The enhanced killing activities are due to increased binding and penetration of the outer membrane of Pseudomonas sp. cells. These properties were not observed in tests of untargeted bacterial species, and this specificity allowed G10KHc to selectively eliminate Pseudomonas spp. from mixed cultures. This work lays a foundation for generating target-specific "smart" antimicrobials to complement currently available conventional antibiotics.
    Antimicrobial Agents and Chemotherapy 05/2006; 50(4):1480-8. DOI:10.1128/AAC.50.4.1480-1488.2006 · 4.45 Impact Factor